Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Lung Cancer

Trial Information

A Phase I Trial of External Beam Radiotherapy Combined with Carboplatin and Paclitaxel Followed by Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) in Unresectable or Medically Inoperable Non-Metastatic CEA-Producing Stage III or IIB Non Small Cell Lung Cancer

You have been asked to participate in this research study because you have a diagnosis of non-small cell lung cancer and your lung cancer produces a protein called carcinoembryonic antigen (CEA). The purpose of this study is to determine the highest dose of a radioactively labeled antibody (Y-90-chimeric T84.66) that can be given after planned standard external beam radiotherapy and chemotherapy without causing unmanageable side effects. Another purpose is to collect data on where the Y-90 anti-CEA goes in the body, what chemical components it breaks down into, how long it takes to leave the body, and what radiation dose it delivers to the whole body, normal organs and tumor. Your treatment on this study is expected to last for 6 months. After your treatment on this study is over, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.